Jerome (“Jerry”) Zeldis, M.D., Ph.D., brings extensive life sciences experience gained primarily through his career at Celgene Inc. He previously served as CEO of Celgene Global Health and chief medical officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where he was employed for nearly 20 years, starting in 1997. Celgene Corporation has been acquired by Bristol Myers-Squibb in a cash and stock deal valued at $74 billion.
“I am very pleased with the progress that has occurred from the time I left the board until now,” commented Dr. Zeldis. “I look forward to the realization of the clinical benefit that may occur by reducing noise in a variety of settings in which detection of small signals is critical for therapeutic interventions.”
Since 2016, Dr. Zeldis has served as chief medical officer and president of Clinical Research, Medical Affairs, Drug Safety, Quality, and Regulatory.
He attended Brown University for an AB, MS, followed by Yale University for an MPhil, M.D., and Ph.D. in molecular biophysics and biochemistry. Dr. Zeldis trained in internal medicine at the UCLA Center for the Health Sciences and in gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was assistant professor of medicine at the Harvard Medical School, associate professor of medicine at University of California, Davis, clinical associate professor of medicine at Cornell Medical School and professor of clinical medicine at the Robert Wood Johnson Medical School in New Brunswick, N.J. Dr. Zeldis is a named inventor on 43 U.S. patents, has published 122 peer reviewed articles and 24 reviews, book chapters and editorials.
“Dr. Zeldis is one of our earliest investors and has watched our company grow from the beginning. He continues to invest in the company. We are eager to work with him to capitalize on his extensive experience in clinical development, regulatory strategy, shareholder wealth creation, and platform development. We are especially excited regarding Jerry’s understanding of bioelectronics medicine and how our PURE EP System can contribute to this rapidly emerging field," stated Kenneth L. Londoner, BioSig Technologies Inc. founder, chairman, and CEO.
Previously, BioSig announced that it successfully conducted first patient cases using its PURE EP System at the Texas Cardiac Arrhythmia Institute in Austin, Greenville Memorial Hospital in Greenville, S.C., and Indiana University School of Medicine. These initial experiences suggested improved cardiac signal detection and fidelity compared to the data acquired using the existing recording devices in the EP lab.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP™System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.